Patents Assigned to Biogen MA Inc.
  • Wearable medical detector
    Patent number: 11147524
    Abstract: Various embodiments of medical detector systems as well as their methods of operation are disclosed. In one embodiment, one or more detectors are coupled to wearable structures for detecting at least a first tracer within a body portion. In another embodiment, one or more detectors are coupled to a wearable structure, where the detector corresponds to a CMOS chip that directly detects a first radioactive tracer.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: October 19, 2021
    Assignee: Biogen MA Inc.
    Inventors: Ajay Verma, Marisa J. Bober, Victoria Cabot, Courtney D. Hilliard, Ara N. Knaian, Seth O. Newburg, John William Hoppin, Karl F. Schmidt
  • Synthesis of thiolated oligonucleotides without a capping step
    Patent number: 11142545
    Abstract: The invention herein describes a solid-phase synthetic method for preparing thiolated oligonucleotides without needing a capping step. The methods of the invention comprises repetition of a three-reaction per cycle, namely detritylation, coupling and sulfurization, without a capping step. In some embodiments, the synthetic methods of the present invention can be used for preparing an anti-sense oligonucleotide.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: October 12, 2021
    Assignee: BIOGEN MA INC.
    Inventors: Xianglin Shi, Jimin Yang, William F. Kiesman, Yannick Fillon
  • Molecular signatures for use in diagnosis and response to treatment analysis of autoimmune diseases
    Patent number: 11142794
    Abstract: The present invention relates to molecular signatures that can be used to identify patients diagnosed with an autoimmune disease, in particular with systemic lupus erythematosus for treatment with a CD40 or CD40L antagonist such as anti-CD40 antibody, anti-CD40L antibody or a binding fragment thereof. The signatures can also be used to monitor target engagement and response to treatment.
    Type: Grant
    Filed: October 4, 2016
    Date of Patent: October 12, 2021
    Assignees: UCB BIOPHARMA SRL, BIOGEN MA INC.
    Inventors: Geoffrey Johnston, Carrie G. Wager, Huo Li, Ann Ranger
  • ARGININE-FREE TNFR:FC-FUSION POLYPEPTIDE COMPOSITIONS AND METHODS OF USE
    Publication number: 20210309719
    Abstract: Aspects of the invention are directed to arginine-free polypeptide-containing compositions and methods for treating disorders associated with inflammation or the autoimmune response. In particular, the polypeptide is etanercept.
    Type: Application
    Filed: March 30, 2021
    Publication date: October 7, 2021
    Applicant: Biogen MA Inc.
    Inventors: Kevin Maloney, Ke Gong, Roy Alston
  • COMBINATION THERAPY FOR SPINAL MUSCULAR ATROPHY
    Publication number: 20210308281
    Abstract: Aspects of the application relate to compositions and methods for treating spinal muscular atrophy in a subject. In particular, this application provides therapeutic combinations of a recombinant nucleic acid that encodes the survival of motor neuron 1 (SMN1) protein (e.g., in a viral vector), and an antisense oligonucleotide (ASO) that increases full-length survival of motor neuron 2 (SMN2) mRNA (e.g., that is targeted to a nucleic acid molecule encoding the survival of motor neuron 2 (SMN2) and that promotes the inclusion of exon 7 in SMN2 mRNA).
    Type: Application
    Filed: August 15, 2019
    Publication date: October 7, 2021
    Applicant: Biogen MA Inc.
    Inventors: Anindya Kumar Sen, Alexander McCampbell
  • ANTI-HSPA5 ANTIBODIES AND USES THEREOF
    Publication number: 20210301002
    Abstract: This disclosure provides anti-HSPA5 antibodies. Also featured is a method for delivering an agent into the brain, spinal cord, or other component of the central nervous system. In addition, methods of identifying a human subject at risk of relapse of neuromyelitis optica (NMO) or neuropsychiatric systemic lupus erythematosus (NP-SLE) are disclosed, as are methods of determining the severity of an attack of NMO or NP-SLE, and methods of diagnosing NP-SLE.
    Type: Application
    Filed: February 23, 2021
    Publication date: September 30, 2021
    Applicants: Biogen MA Inc., The Regents of the University of Colorado, a body corporate
    Inventors: Jeffrey L. Bennett, Richard M. Ransohoff, Fumitaka Shimizu, Kristin L. Schaller
  • Methods of treating multiple sclerosis
    Patent number: 11129806
    Abstract: Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: September 28, 2021
    Assignee: Biogen MA Inc.
    Inventors: Mark Novas, Rui (Ray) Zhang
  • Methods for overcoming glutamine deprivation during mammalian cell culture
    Patent number: 11124760
    Abstract: The present invention pertains to methods of producing polypeptide of interest in cell cultures lacking glutamine. The present invention further pertains to a method of producing a protein of interest in a large scale cell culture, comprising supplementing the cell culture with nucleic acid synthesis precursors and/or corticosteroids.
    Type: Grant
    Filed: March 24, 2015
    Date of Patent: September 21, 2021
    Assignees: Biogen MA Inc., Samsung Bioepis
    Inventors: William Yang, Yao-Ming Huang, Marty Sinacore, Thomas Ryll, Jiuyi Lu, Jaesun Lee, Kyngju Lee, Hyoung Taek Lim, Eunchong Yang
  • Injector lockout prevention device
    Patent number: 11116911
    Abstract: A device that prevents the accidental activation and lockout of an autoinjector. In illustrative embodiments, a resistance unit is configured to resist deployment of the needle until a critical force is applied by the user to the autoinjector, at which point, the resistance of the resistance unit is overcome. Continuous application of force by the user after the resistance is overcome drives the delivery device to the injection site where the medication is administered.
    Type: Grant
    Filed: April 11, 2017
    Date of Patent: September 14, 2021
    Assignee: BIOGEN MA, INC.
    Inventor: Haiming Wu
  • Anti-BCMA antibodies
    Patent number: 11111307
    Abstract: This invention provides antibodies that recognize the B Cell Maturation Antigen (BCMA) and that bind naïve B cells, plasma cells, and/or memory B cells. The invention further provides methods for depleting naïve B cells, plasma cells, and memory B cells, and for treating B cell-related disorders, including lymphomas and autoimmune diseases.
    Type: Grant
    Filed: July 3, 2018
    Date of Patent: September 7, 2021
    Assignee: Biogen MA Inc.
    Inventors: Susan L. Kalled, Yen-Ming Hsu
  • Hydrophobic interaction protein chromatography under no-salt conditions
    Patent number: 11111269
    Abstract: Various aspects and embodiments of the present disclosure relate to the purification antibodies by hydrophobic interaction chromatography under no-salt conditions.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: September 7, 2021
    Assignee: Biogen MA Inc.
    Inventors: Sanchayita Ghose, Yinying Tao
  • Combination Therapies and Uses for Treatment of Demyelinating Disorders
    Publication number: 20210260185
    Abstract: Methods and compositions for enhancing one or more of: myelination, re-myelination, oligodendrocyte numbers, or neuroaxonal protection, while ameliorating an inflammatory condition in a human subject are disclosed. In certain embodiments, the methods and compositions described herein include a reparative agent (e.g., a LINGO-1 antagonist) and an immunomodulatory agent, in combination. Thus, methods, compositions and kits described herein can be useful for treating a CNS demyelinating disease.
    Type: Application
    Filed: November 30, 2020
    Publication date: August 26, 2021
    Applicant: Biogen MA Inc.
    Inventors: Diego Cadavid, Sha Mi
  • NUCLEAR TRANSPORT MODULATORS AND USES THEREOF
    Publication number: 20210251968
    Abstract: Compounds of formula I: and pharmaceutically acceptable salts, solvates, or hydrates thereof, pharmaceutical compositions comprising the compounds of formula I, and methods of making and using the compounds, salts, solvates, or hydrates and the compositions in the treatment of various disorders associated with CRM1 activity.
    Type: Application
    Filed: February 19, 2021
    Publication date: August 19, 2021
    Applicant: Biogen MA Inc.
    Inventors: Vincent P. Sandanayaka, Sharon Shechter, Sharon Shacham, Dilara McCauley, Erkan Baloglu
  • Anti-VLA-4 antibodies
    Patent number: 11083791
    Abstract: This invention relates to alpha-4 binding antibodies, and fragments thereof.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: August 10, 2021
    Assignee: Biogen MA Inc.
    Inventors: Alexey A. Lugovskoy, Frederick R. Taylor, Karen McLachlan
  • ANTI-VLA-4 ANTIBODIES HAVING REDUCED EFFECTOR FUNCTION
    Publication number: 20210238289
    Abstract: The invention relates to anti-VLA-4 antibodies and binding fragments thereof. The invention further includes polynucleotides encoding said antibodies and binding fragments thereof and methods of manufacturing said antibodies and binding fragments thereof. The invention further includes methods of treating patients suffering from multiple sclerosis and/or epilepsy by administration of said antibodies and binding fragments thereof. The invention further includes methods of reducing the susceptibility to scrambling of a recombinant anti-alpha 4 antibody or a binding fragment thereof.
    Type: Application
    Filed: May 31, 2019
    Publication date: August 5, 2021
    Applicant: BIOGEN MA INC.
    Inventors: Janine Lisa FERRANT-ORGETTAS, Robert Blake PEPINSKY, Ellen Duggan CAHIR-MCFARLAND, Nadia Giselle D'LIMA, Joseph Walter ARNDT, Karl John Mortley HANF, Thomas Owen CAMERON, Ellen Garber STARK
  • Methods for determining differences in alpha-4 integrin activity by correlating differences in sVCAM and/or sMAdCAM levels
    Patent number: 11079393
    Abstract: Provided herein is a method of monitoring the change of the alpha-4 integrin activities in an individual by correlating with the soluble vascular cell adhesion molecule (sVCAM) and/or soluble mucosal addressin cell adhesion molecule (sMAdCAM) levels. Particularly, this method can be used, for example, to evaluate the pharmacokinetics and pharmacodynamics (PK/PD) of an alpha-4 integrin inhibitor used to treat a disease associated with pathological or chronic inflammation.
    Type: Grant
    Filed: April 18, 2016
    Date of Patent: August 3, 2021
    Assignee: BIOGEN MA INC.
    Inventor: Alissa A. Chackerian
  • Dimethyl Fumarate and Vaccination Regimens
    Publication number: 20210228701
    Abstract: Provided herein is a method of treating or preventing a disease or disorder (e.g., MS) in a subject in need thereof, comprising (a) administering to the subject a first dose of a pharmaceutical composition comprising a fumarate agent (e.g., DMF) for a first dosing period; (b) administering a vaccine; and (c) administering to the subject a second dose of the pharmaceutical composition for a second dosing period.
    Type: Application
    Filed: April 12, 2021
    Publication date: July 29, 2021
    Applicant: Biogen MA Inc.
    Inventor: Vissia Viglietta
  • Compounds and methods for reducing Tau expression
    Patent number: 11053498
    Abstract: Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of Tau mRNA in a cell or animal, and in certain instances reducing the amount of Tau protein in a cell or animal. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom of a neurodegenerative disease. Such symptoms include loss of memory, loss of motor function, and increase in the number and/or volume of neurofibrillary inclusions. Such neurodegenerative diseases include tauopathies, Alzheimer's Disease, Fronto-temporal Dementia (FTD), FTDP-17, Progressive Supranuclear Palsy (PSP), Chronic Traumatic Encephalopathy (CTE), Corticobasal Ganglionic Degeneration (CBD), Epilepsy, and Dravet's Syndrome.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: July 6, 2021
    Assignee: Biogen MA Inc.
    Inventor: Holly Kordasiewicz
  • Compositions and methods for assessing neuromuscular function
    Patent number: 11040119
    Abstract: The invention provides compositions and methods for evaluating neuromuscular function in a subject, e.g., a subject at risk for or suffering from a neuromuscular disorder.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: June 22, 2021
    Assignee: Biogen MA Inc.
    Inventors: Ajay Verma, Jack Hoppin
  • Pharmaceutical bead formulations comprising dimethyl fumarate
    Patent number: 11033509
    Abstract: The present invention provides novel pharmaceutical compositions of dimethyl fumarate. The pharmaceutical compositions of the present invention comprises a first pharmaceutical bead composition and a second pharmaceutical bead composition, wherein the first pharmaceutical bead composition is an enterically coated immediate-release composition and the second pharmaceutical bead composition is an enterically coated controlled-release composition, wherein the first pharmaceutical bead composition and the second pharmaceutical bead composition both comprise dimethyl fumarate Methods of using the pharmaceutical compositions of the present invention for treating multiple sclerosis are also included.
    Type: Grant
    Filed: February 8, 2017
    Date of Patent: June 15, 2021
    Assignee: BIOGEN MA INC.
    Inventors: Shyam B. Karki, Peter Zawaneh, Cheuk-Yui Leung, Kalyan Vasudevan, Yiqing Lin, Jin Xu, Andrea Trementozzi, Ivan Nestorov